The problem with six weeks of daily treatment
Standard TMS protocols for depression require 30-36 sessions delivered once daily, five days a week, over six to seven weeks. The treatment works — response rates of 50-60% are well documented — but the time commitment is a genuine barrier.
Six weeks of daily clinic visits means rearranging work schedules, arranging childcare, managing transportation, and committing to a routine that a lot of people find logistically difficult. If you’re traveling from a rural area to reach a TMS provider, the burden is even greater. Some people who would benefit from TMS never start. Others begin treatment but drop out before completing the full course, compromising their outcomes.
Accelerated TMS protocols aim to solve this by delivering the same total stimulation dose — or even a higher one — over a dramatically compressed timeline. Instead of one session per day for six weeks, what if you could do multiple sessions per day and finish in one to two weeks? Or even five days?
The research says you can. And the results may actually be better.
The Stanford Neuromodulation Therapy (SNT) protocol
The SAINT trial (Cole et al., 2020)
Citation: Cole EJ, Stimpson KH, Bentzley BS, et al. “Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression.” American Journal of Psychiatry. 2020;177(8):716-726.
The study that changed the conversation about accelerated TMS. Nolan Williams and colleagues at Stanford University tested an intensive protocol that was radically different from anything tried before.
The protocol delivered 10 sessions per day of intermittent theta burst stimulation (iTBS), with 50-minute intervals between sessions, over 5 consecutive days — a total of 50 sessions (1,800 pulses each) in one week. Each session lasted about 10 minutes including setup.
Two innovations made SAINT more than a “do more, faster” approach:
Personalized targeting. Instead of using the standard 5-cm rule or even generic MRI coordinates, the Stanford team used each person’s individual resting-state fMRI to identify the specific DLPFC subregion most strongly connected to the subgenual anterior cingulate cortex (sgACC). This neuroimaging-guided targeting ensured that stimulation hit the precise spot most likely to engage the mood-regulating circuit.
Optimized inter-session interval. The 50-minute gap between sessions wasn’t arbitrary. It was based on basic neuroscience research on LTP metaplasticity — the finding that a second bout of stimulation delivered roughly 50 minutes after the first produces stronger synaptic strengthening than either continuous stimulation or longer intervals.
The results
The initial open-label SAINT data (22 participants) were remarkable: 90.5% response rate (defined as >50% reduction in depression scores) and 86.4% remission rate (19 of 22 participants). The mean time to treatment response was just 2.3 days — most people showed significant improvement by the third day, after approximately 23 sessions. At one-month follow-up, 70% of participants continued to show treatment response.
The double-blind confirmation (Cole et al., 2022)
Citation: Cole EJ, Phillips AL, Bentzley BS, et al. “Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial.” American Journal of Psychiatry. 2022;179(2):132-141.
The subsequent double-blind sham-controlled trial confirmed the findings with more rigor. At the planned interim analysis, 32 participants had been enrolled; 29 who continued to meet inclusion criteria received either active (n=14) or sham (n=15) SNT.
- Active group: 52.5% mean reduction in MADRS score at 4 weeks post-treatment
- Sham group: 11.1% mean reduction in MADRS score
These numbers are dramatically higher than any previous TMS trial. The effect size (Cohen’s d = 1.65) was among the largest ever reported for any depression treatment.
Follow-up data showed durable benefits, with most responders maintaining improvement at one month and many sustaining it longer. The rapid onset — substantial improvement within days rather than weeks — raised the possibility that accelerated TMS could work for urgent situations previously thought to require ECT.
Other accelerated approaches
Stanford’s protocol is the most studied, but it’s not the only accelerated TMS approach being tested.
Twice-daily protocols
Several research groups have tested twice-daily TMS sessions (morning and afternoon) using standard 10 Hz rTMS. A 2019 study by Fitzgerald and colleagues in Australia found that twice-daily treatment over two weeks produced outcomes comparable to standard once-daily treatment over four weeks. Response rates were similar, and people tolerated it well.
Twice-daily protocols are less aggressive than SAINT’s 10-sessions-per-day approach and may hit a practical sweet spot for clinics that want to offer faster treatment without the infrastructure required for Stanford-level intensity.
Three-times-daily iTBS
Building on the THREE-D trial’s validation of theta burst stimulation as equivalent to standard rTMS, several groups have tested three iTBS sessions per day with 15-minute to one-hour intervals between sessions. These protocols can deliver a full treatment course in about two weeks. Early results are promising, with response and remission rates comparable to or slightly higher than standard once-daily approaches.
Weekend intensive protocols
A novel approach being tested at Columbia University delivers standard-length TMS courses but concentrates sessions into fewer calendar days, including weekends. Instead of five sessions over five weekdays with two rest days, you receive sessions seven days a week. This cuts total treatment duration from six weeks to about four weeks without changing the daily dose.
Multi-session-per-day safety data
The most common concern about accelerated protocols: safety. If one session per day is safe, are ten sessions per day also safe?
The evidence is reassuring:
Seizure risk: No seizures have been reported in any published accelerated TMS trial, including the SAINT protocol. The inter-session intervals allow neurons to return to baseline excitability before the next stimulation bout, and the total daily pulse count, while high, remains within bounds that basic neuroscience research suggests are safe.
Scalp discomfort: Accelerated protocols do produce more scalp soreness than standard protocols, particularly during the first two days. Most people describe it as mild to moderate and manageable with OTC painkillers. By day three, you typically get used to it.
Fatigue: Many people in the SAINT trials reported significant fatigue during the treatment week, which makes sense given the intensity. This fatigue resolved within days of completing treatment.
Cognitive effects: Formal neuropsychological testing in the SAINT trials showed no cognitive impairment — consistent with the broader TMS vs ECT evidence showing that TMS doesn’t hurt cognition. Some people actually showed cognitive improvement, likely because their mood was better.
Headache: Transient headaches are slightly more common with accelerated protocols than standard ones, but remain mild and self-limiting.
A 2023 safety review pooling data from multiple accelerated TMS studies with over 500 patients concluded that multi-session-per-day protocols, when delivered with appropriate inter-session intervals and standard safety monitoring, carry a risk profile comparable to standard once-daily TMS.
Why accelerated protocols might actually work better
The superior efficacy of the SAINT protocol — if confirmed in larger trials — may not be solely due to the compressed timeline. Several features of the approach could independently contribute to better outcomes:
Personalized targeting likely explains a big chunk of the improvement. Standard TMS uses an anatomical approximation that misses the optimal stimulation point in many people. fMRI-guided targeting ensures the right spot is hit, session after session.
Higher total dose. The SAINT protocol delivers 90,000 total pulses over five days. Standard protocols deliver 54,000-108,000 pulses over six weeks. The concentrated delivery may produce stronger neuroplastic effects than the same dose spread over a longer period.
Metaplasticity optimization. The 50-minute inter-session interval exploits metaplasticity — the phenomenon where prior synaptic activity changes the threshold and magnitude of subsequent plasticity. This timing may amplify LTP effects beyond what single daily sessions can achieve.
Reduced dropout. One-week protocols have near-zero dropout rates. Standard six-week protocols lose 10-20% of people to non-completion. Every person who drops out is a potential responder who never got the chance to respond.
Costs
Accelerated TMS protocols have complex cost implications:
Direct costs: More sessions per day means higher daily facility costs, but fewer total treatment days means lower cumulative costs for staff time, scheduling overhead, and facility use. In the SAINT model, the total treatment requires five days of intensive clinic use versus 30+ separate visit days.
Indirect costs: You save roughly 25 days of work and travel compared to standard protocols. For working people, that’s thousands of dollars in preserved income and reduced opportunity cost.
System costs: Faster treatment means higher throughput. A clinic that can complete a treatment course in five days rather than six weeks can serve six to eight times as many people with the same equipment, potentially cutting wait times and expanding access in underserved areas.
The infrastructure caveat: Running SAINT-level protocols requires fMRI capability for targeting, neuronavigation equipment, and staff willing to manage 10-session treatment days. Not every clinic can — or should — offer this level of intensity. Finding a clinic with the right equipment and experience matters.
Early health-economic modeling suggests that accelerated protocols, despite higher per-day costs, are cost-effective or even cost-saving compared to standard TMS when indirect costs and productivity are factored in.
Where the field is heading
Accelerated TMS is moving from research innovation to clinical reality. Several TMS technology companies are developing commercial systems optimized for accelerated delivery, including integrated neuronavigation and automated targeting.
Large multi-site replication trials for the SAINT protocol are underway, and results are expected to inform potential new FDA clearance pathways specifically for accelerated approaches. If the efficacy and safety data hold up at scale, accelerated TMS could become the default protocol within a few years — making the current six-week standard a relic of an earlier era.
If you’re interested in accelerated TMS, the key questions to ask your clinic: Do they use fMRI-guided or neuronavigation-guided targeting? What inter-session interval do they use? How many total sessions are in their protocol? And what does their own outcome data look like?
To find out whether accelerated TMS is available near you, browse our provider directory or connect with a TMS specialist who stays current with the latest research.